PURPOSE: Lung cancer is a global health problem, with more than 220,000 new cases and 150,000 deaths per year in the United States. Likewise, in Brazil, lung cancer is the most lethal cancer with 30,200 new cases expected in 2020. Regarding treatment types, radiation therapy (RT) represents an important approach, since 60%-70% of the patients will receive this modality of treatment during the course of their disease. However, access to RT remains challenging because of the socioeconomic inequalities in the Brazilian population, where approximately 100,000 patients/year die without access to RT. This work provides an overview on the availability of high technology RT in Brazil. METHODS: A retrospective study was performed using the Brazilian Radiotherapy Census, local public and private databases, and the current literature published in 2019. RESULTS: The Brazilian radiotherapy network relies on approximately 363 linear accelerators and 20 cobalt machines that remain operational. Most of these machines are installed at public health facilities. Regarding high technology, intensity-modulated RT is available in 53.7% (n = 130) and volumetric modulated arc therapy in 28.5% (n = 69) of the institutions, although only 19.8% (n = 48) of those facilities are capable of performing image-guided RT using cone beam computed tomography. Considering only the public health care system, the scenario is more restricted, with 40.1% (n = 65) of the institutions offering intensity-modulated RT, 21% (n = 34) volumetric modulated arc therapy, and 14.8% (n = 24) using cone beam computed tomography. Because of these scare resources, only 16% of Radiation Departments offer stereotactic body RT. CONCLUSION: Brazil still needs to improve and provide high and safer RT technologies to patients with lung cancer across all Brazilian regions to attend the population needs and obtain better patient outcomes.
PURPOSE: Lung cancer is a global health problem, with more than 220,000 new cases and 150,000 deaths per year in the United States. Likewise, in Brazil, lung cancer is the most lethal cancer with 30,200 new cases expected in 2020. Regarding treatment types, radiation therapy (RT) represents an important approach, since 60%-70% of the patients will receive this modality of treatment during the course of their disease. However, access to RT remains challenging because of the socioeconomic inequalities in the Brazilian population, where approximately 100,000 patients/year die without access to RT. This work provides an overview on the availability of high technology RT in Brazil. METHODS: A retrospective study was performed using the Brazilian Radiotherapy Census, local public and private databases, and the current literature published in 2019. RESULTS: The Brazilian radiotherapy network relies on approximately 363 linear accelerators and 20 cobalt machines that remain operational. Most of these machines are installed at public health facilities. Regarding high technology, intensity-modulated RT is available in 53.7% (n = 130) and volumetric modulated arc therapy in 28.5% (n = 69) of the institutions, although only 19.8% (n = 48) of those facilities are capable of performing image-guided RT using cone beam computed tomography. Considering only the public health care system, the scenario is more restricted, with 40.1% (n = 65) of the institutions offering intensity-modulated RT, 21% (n = 34) volumetric modulated arc therapy, and 14.8% (n = 24) using cone beam computed tomography. Because of these scare resources, only 16% of Radiation Departments offer stereotactic body RT. CONCLUSION: Brazil still needs to improve and provide high and safer RT technologies to patients with lung cancer across all Brazilian regions to attend the population needs and obtain better patient outcomes.
Authors: Kyle G Mitchell; Ahsan Farooqi; Ethan B Ludmir; Erin M Corsini; Jiexin Zhang; Boris Sepesi; Ara A Vaporciyan; Stephen G Swisher; John V Heymach; Jianjun Zhang; Daniel R Gomez; Mara B Antonoff Journal: Clin Lung Cancer Date: 2019-08-01 Impact factor: 4.785
Authors: Benjamin D Smith; Jing Jiang; Joe Y Chang; James Welsh; Anna Likhacheva; Thomas A Buchholz; Stephen G Swisher; Shervin M Shirvani Journal: J Geriatr Oncol Date: 2015-06-17 Impact factor: 3.599
Authors: Rifat Atun; David A Jaffray; Michael B Barton; Freddie Bray; Michael Baumann; Bhadrasain Vikram; Timothy P Hanna; Felicia M Knaul; Yolande Lievens; Tracey Y M Lui; Michael Milosevic; Brian O'Sullivan; Danielle L Rodin; Eduardo Rosenblatt; Jacob Van Dyk; Mei Ling Yap; Eduardo Zubizarreta; Mary Gospodarowicz Journal: Lancet Oncol Date: 2015-09 Impact factor: 41.316
Authors: Dario Pasalic; Yi Lu; Sonia L Betancourt-Cuellar; Nicolette Taku; Shane M Mesko; Alexander F Bagley; William W Chance; Pamela K Allen; Chad Tang; Mara B Antonoff; Peter A Balter; Reza J Mehran; James W Welsh; Zhongxing Liao; Daniel Gomez; Jeremy J Erasmus; Quynh-Nhu Nguyen Journal: Radiother Oncol Date: 2020-02-07 Impact factor: 6.280
Authors: Carlos Eduardo Cintra Vita Abreu; Paula Pratti Rodrigues Ferreira; Fabio Ynoe de Moraes; Wellington Furtado Pimenta Neves; Rafael Gadia; Heloisa de Andrade Carvalho Journal: J Bras Pneumol Date: 2015 Jul-Aug Impact factor: 2.624
Authors: Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach Journal: Lancet Oncol Date: 2016-10-24 Impact factor: 41.316